Table 1 Clinical and demographic characteristics of Parsonage–Turner syndrome cases associated with COVID-19 vaccination published in the literature
Study | COVID-19 vaccine | Dose | Immunization schedule completed | Age | Sex | Time to onset of first symptoms | Motor symptoms | Sensory symptoms | Altered ENMG | Treatment | Recovery |
|---|---|---|---|---|---|---|---|---|---|---|---|
Mahajan et al. | BNT162b (Comirnaty, Pfizer-BioNtech) | First | Yes | 50 years old | M | 7 days | Hand grip and wrist extension weakness | Pain | Yes | NSAID Corticosteroids | Partial recovery |
Diaz-Segarra et al. | BNT162b (Comirnaty, Pfizer-BioNtech) | First | NA | 35 years old | F | 9 days | Arm weakness | Numbness and paresthesias | Yes | Corticosteroids | Partial recovery |
Crespo Burillo et al. | ChAdOx1-S (Vaxzevria, AstraZeneca) | First | NA | 38 years old | M | 4 days | No | Pain | Yes | NSAID Corticosteroids Physiotherapy | Full recovery |
Present case | ChAdOx1-S (Vaxzevria, AstraZeneca) | First | No | 51 years old | M | 4 days | Proximal muscle weakness of the left upper limb | Pain Hypoesthesia | Yes | NSAID Paracetamol Pregabalin Physiotherapy | Partial recovery |